Serotonin-1A receptor CC genotype is associated with persistent depression related to interferon-alpha in hepatitis C patients

General Hospital Psychiatry

Volumn 36, Issue 3, 2014, Pages 255-260

  Galvão de Almeida, Amanda ^a,b   Quarantini, Lucas C ^a   Tartaglioni, Amanda Guindalini ^b   Lyra, André C ^a   Parise, Carmen Lívia ^b   Paraná, Raymundo ^a   de Oliveira, Irismar R ^a   Miranda Scippa, Ângela ^a,b   Guindalini, Camila ^a,b  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Interferon alpha; Major depressive disorder; Serotonin receptor; Serotonin transporter

Indexed keywords

ALPHA INTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA PLUS RIBAVIRIN; RIBAVIRIN; SEROTONIN 1A RECEPTOR; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; ANTIVIRUS AGENT;

5 HTR GENE; 5 HTR1A GENE; 5 HTT GENE; 5 HTTLPR GENE; ADULT; AMPLIFIED FRAGMENT LENGTH POLYMORPHISM; ARTICLE; CROSS-SECTIONAL STUDY; DEPRESSION; DISEASE ASSOCIATION; FEMALE; GENE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; CHEMICALLY INDUCED; GENETICS; MAJOR DEPRESSION; MIDDLE AGED;

ANTIVIRAL AGENTS; DEPRESSIVE DISORDER, MAJOR; GENOTYPE; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RECEPTOR, SEROTONIN, 5-HT1A; RIBAVIRIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 84898837314     PISSN: 01638343     EISSN: 18737714     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2013.12.007     Document Type: Article

References (58)

1. Capuron L., Miller A.H. Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry 2004, 56(11):819-824.
2. Raison C.L., Borisov A.S., Majer M., et al. Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol Psychiatry 2009, 65(4):296-303.
3. Comai S., Cavalletto L., Chemello L., et al. Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C. Pharmacol Res 2011, 63(1):85-92.
4. Keefe B. Interferon-induced depression in hepatitis C: an update. Curr Psychiatry Rep 2007, 9(3):255-261.
5. Kraus M.R., Schafer A., Faller H., Csef H., Scheurlen M. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002, 16(6):1091-1099.
6. Diez-Quevedo C., Masnou H., Planas R., et al. Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011, 72(4):522-528.
7. Galvão-de Almeida A., Guindalini C., Batista-Neves S., de Oliveira I.R., Miranda-Scippa A., Quarantini L.C. Can antidepressants prevent interferon-alpha-induced depression? A review of the literature. Gen Hosp Psychiatry 2010, 32(4):401-405.
8. Morasco B.J., Loftis J.M., Indest D.W., et al. Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial. Psychosomatics 2010, 51(5):401-408.
9. Quarantini L.C., Miranda-Scippa A., Batista-Neves S., et al. A neuropsychological study comparing patients infected with HCV and HBV without psychiatric comorbidities. J Med Virol 2009, 81(7):1184-1188.
10. Quarantini L.C., Miranda-Scippa A., Schinoni M.I., et al. Effect of amantadine on depressive symptoms in chronic hepatitis C patients treated with pegylated interferon: a randomized, controlled pilot study. Clin Neuropharmacol 2006, 29(3):138-143.
11. Hayley S., Poulter M.O., Merali Z., Anisman H. The pathogenesis of clinical depression: stressor- and cytokine-induced alterations of neuroplasticity. Neuroscience 2005, 135(3):659-678.
12. Schiepers O.J., Wichers M.C., Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29(2):201-217.
13. Bonaccorso S., Marino V., Puzella A., et al. Increased depressive ratings in patients with hepatitis C receiving interferon-based immunotherapy are related to interferon-induced changes in the serotonergic system. J Clin Psychopharmacol 2002, 22(1):86-90.
14. Capuron L., Neurauter G., Musselman D.L., et al. Interferon-induced changes in tryptophan metabolism: relationship to depression and paroxetine treatment. Biol Psychiatry 2003, 54(9):906-914.
15. Quarantini L.C., Miranda-Scippa A., Parana R., Sampaio A.S., Bressan R.A. Acute dystonia after injection of pegylated interferon alpha-2b. Mov Disord 2007, 22(5):747-748.
16. Morikawa O., Sakai N., Obara H., Saito N. Effects of interferon-α, interferon-γ, and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol 1998, 349(2-3):317-324.
17. Caspi A., Sugden K., Moffitt T.E., et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003, 301(5631):386-389.
18. Bull S.J., Huezo-Diaz P., Binder E.B., et al. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry 2009, 14(12):1095-1104.
19. Kaufman J., Yang B.-Z., Douglas-Palumberi H., et al. Brain-derived neurotrophic factor-5-HTTLPR gene interactions and environmental modifiers of depression in children. Biol Psychiatry 2006, 59(8):673-680.
20. Nakamura M., Ueno S., Sano A., Tanabe H. The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol Psychiatry 2000, 5(1):32-38.
21. Kraus M.R., Al-Taie O., Schäfer A., Pfersdorff M., Lesch K.P., Scheurlen M. Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C. Gastroenterology 2007, 132(4):1279-1286.
22. Lotrich F.E., Ferrell R.E., Rabinovitz M., Pollock B.G. Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol Psychiatry 2009, 65(4):344-348.
23. Pierucci-Lagha A., Covault J., Bonkovsky H.L., et al. A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment. Psychosomatics 2010, 51(2):137-148.
24. Hensler J.G. Regulation of 5-HT1A receptor function in brain following agonist or antidepressant administration. Life Sci 2003, 72(15):1665-1682.
25. Navines R., Gomez E., Gasto C. The 5-HT1A receptors: from molecular biology to neuropsychiatric symptoms. Actas Esp Psiquiatr 2003, 31(5):272-283.
26. Naughton M., Mulrooney J.B., Leonard B.E. A review of the role of serotonin receptors in psychiatric disorders. Hum Psychopharmacol 2000, 15(6):397-415.
27. Lopez-Figueroa A.L., Norton C.S., Lopez-Figueroa M.O., et al. Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia. Biol Psychiatry 2004, 55(3):225-233.
28. Cai W., Khaoustov V.I., Xie Q., Pan T., Le W., Yoffe B. Interferon-α-induced modulation of glucocorticoid and serotonin receptors as a mechanism of depression. J Hepatol 2005, 42(6):880-887.
29. Smith A.K., Simon J.S., Gustafson E.L., et al. Association of a polymorphism in the indoleamine- 2,3-dioxygenase gene and interferon-α-induced depression in patients with chronichepatitis C. Mol Psychiatry 2012, 17(8):781-789.
30. Galvão-de Almeida A., Quarantini L.C., Sampaio A.S., et al. Lack of association of indoleamine 2,3-dioxygenase polymorphisms with interferon-alpha-related depression in hepatitis C. Brain Behav Immun 2011, 25(7):1491-1497.
31. Galvão-de Almeida A., Quarantini L.C., Batista-Neves S., et al. Is the interferon-α-triggered depressive episode a self-limited kind of depression? Four cases of persistent affective symptoms after antiviral treatment in HCV-infected individuals. World J Biol Psychiatry 2010, 11(7):914-918.
32. Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24(2):289-293.
33. Amorim P. Mini International Neuropsychiatric Interview (MINI): validação de entrevista breve para diagnóstico de transtornos mentais. Rev Bras Psiquiatr 2000, 22(3):106-115.
34. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Press, Washington, DC. 4th ed.
35. World Health Organization International classification of diseases 1991, World Health Organization, Geneva. 10th ed.
36. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16(3):1215.
37. Myakishev M.V., Khripin Y., Hu S., Hamer D.H. High-throughput SNP genotyping by allele-specific PCR with universal energy-transfer-labeled primers. Genome Res 2001, 11(1):163-169.
38. Shriver M.D., Mei R., Parra E.J., et al. Large-scale SNP analysis reveals clustered and continuous patterns of human genetic variation. Hum Genomics 2005, 2(2):81-89.
39. Guindalini C., Howard M., Haddley K., et al. A dopamine transporter gene functional variant associated with cocaine abuse in a Brazilian sample. Proc Natl Acad Sci U S A 2006, 103(12):4552-4557.
40. Pritchard J.K., Stephens M., Donnelly P. Inference of population structure using multilocus genotype data. Genetics 2000, 155(2):945-959.
41. Galvão-de Almeida A., Miranda-Scippa A., De Oliveira I.R., Quarantini L. Interferon-α as an appropriate model of substance-induced depression. Psychosomatics 2011, 52(1):95.
42. Su K.P., Huang S.Y., Peng C.Y., et al. Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels. Biol Psychiatry 2010, 67(6):550-557.
43. Wichers M., Maes M. The psychoneuroimmuno-pathophysiology of cytokine induced depression in humans. Int J Neuropsychopharmacol 2002, 5(4):375-388.
44. Maes M., Leonard B.E., Myint A.M., Kubera M., Verkerk R. The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(3):702-721.
45. Horikawa N., Yamazaki T., Izumi N., Uchihara M. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen Hosp Psychiatry 2003, 25(1):34-38.
46. Schaefer M., Engelbrecht M.A., Gut O., et al. Interferon alpha (IFN-alpha) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26(4):731-746.
47. Capuron L., Ravaud A. Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state. N Engl J Med 1999, 340(17):1370.
48. Otsubo T., Miyaoka H., Kamijima K., Onuki M., Ishii M., Mitamura K. Depression during interferon therapy in chronic hepatitis C patients. Seishin Shinkeigaku Zasshi 1997, 99(3):101-127.
49. Schäfer A., Wittchen H.U., Seufert J., Kraus M.R. Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C - a critical review. Int J Methods Psychiatr Res 2007, 16(4):186-201.
50. Telio D., Sockalingam S., Stergiopoulos V. Persistent psychosis after treatment with interferon alpha: a case report. J Clin Psychopharmacol 2006, 26(4):446-447.
51. Monji A., Yoshida I., Tashiro K., Hayashi Y., Tashiro N. A case of persistent manic depressive illness induced by interferon-alfa in the treatment of chronic hepatitis C. Psychosomatics 1998, 39(6):562-564.
52. Reichenberg A., Gorman J.M., Dieterich D.T. Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. AIDS 2005, 19(Suppl. 3):S174-S178.
53. Gohier B., Goeb J.L., Rannou-Dubas K., Fouchard I., Calès P., Garré J.B. Hepatitis C, alpha interferon, anxiety and depression disorders: a prospective study of 71 patients. World J Biol Psychiatry 2003, 4(3):115-118.
54. Schmidt F., Janssen G., Martin G., et al. Factors influencing long-term changes in mental health after interferon-alpha treatment of chronic hepatitis C. Aliment Pharmacol Ther 2009, 30(10):1049-1059.
55. Batista-Neves S.C., Quarantini L.C., de Almeida A.G., et al. High frequency of unrecognized mental disorders in HCV-infected patients. Gen Hosp Psychiatry 2008, 30(1):80-82.
56. Udina M., Moreno-España J., Navinés R., et al. Serotonin and interleukin-6: the role of genetic polymorphisms in IFN-induced neuropsychiatric symptoms. Psychoneuroendocrinology 2013, 38(9):1803-1813.
57. Lotrich F.E., Loftis J.M., Ferrell R.E., et al. IL28B polymorphism is associated with both side effects and clearance of hepatitis C during interferon-alpha therapy. J Interferon Cytokine Res 2011, 31(3):331-336.
58. Lotrich F.E., Ferrell R.E., Rabinovitz M., et al. Labile anger during interferon alfa treatment is associated with a polymorphism in tumor necrosis factor alpha. Clin Neuropharmacol 2010, 33(4):191-197.